Innovation to Impact: Drug Development, AI, and Regulatory Strategy
We examine how high-stakes go/no-go calls are made inside pharma and biotech, and what evidence is required for new tools to change those decisions without creating hidden risk.
Each episode focuses on predictivity, translational risk, decision rights, and accountability (what breaks, who owns it, and what triggers a stop).
This is not a podcast about technology trends. It is about disciplined innovation that can survive audit, scale, and real-world biology.
7 episodes • 0 archived •